ALISO VIEJO, Calif.– GE Healthcare announced today that Clarient Diagnostic Services, Inc., a GE Healthcare company, will begin offering a next-generation sequencing assay focused on solid tumor targets for use in clinical trials. This assay will empower researchers to perform prospective and retrospective analysis to better understand which patients will respond to particular therapies, to […]
Austin, Texas – Asuragen Inc., a leading molecular diagnostic company, announced today the launch of its SuraSeq™ Next Generation Sequencing (NGS) Service in its GLP compliant Genomics Services Laboratory. Asuragen’s SuraSeq™ NGS Service was developed specifically for targeted DNA mutation analysis from FFPE and FNA tumor samples to identify both known and de novo mutations. […]
MENLO PARK, CA — LamdaGen Corporation, a nano-technology platform company that provides plasmonic sensors and systems for diagnostics and life sciences, announced the Japanese Patent Office issuance of patent number 5203390, “Enzymatic Assays for LSPR”, which enables highly sensitive and quantitative diagnostics. “The issuance of this patent underscores LamdaGen’s unique ability to harness the significant […]
Aliso Viejo, CA –– Ambry Genetics announced today that they have launched a somatic variant detection service, developed in collaboration with Illumina. This service complements Ambry’s extensive menu of next-generation sequencing services and portfolio of diagnostic genetic testing panels for hereditary cancers. Ambry Genetics has offered next-generation sequencing services since 2007 and has been at […]
SANTA CLARA, CA: NextBio and Genophen announced today a partnership aimed at furthering the adoption of genomics for disease prevention and wellness. The partnership enables Genophen to interpret full genome sequencing data from individuals through the use of the NextBio Clinical platform and to combine this data with a person’s environmental, behavioral and clinical factors […]
Lexington, MA, – T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the U.S. Patent and Trademark Office has issued a patent, number US8,409,807 (the ‘807 patent), covering T2Candida®, the Company’s flagship diagnostic test. T2Candida identifies sepsis-causing Candida species directly from whole blood at ~1CFU/mL sensitivity in approximately three hours compared […]
SAN DIEGO, CA – Genalyte, Inc. today announced the launch of its MT-ADATM anti-drug antibody (ADA) immunogenicity assay designed to run on the MaverickTM Detection System. This test combines screening for the presence of ADAs and the characterization of each detected ADA with a full isotype profile. With minimal required sample preparation and its combination […]
GLOSTRUP, Denmark, – Dako, an Agilent Technologies Company and worldwide provider of cancer diagnostics, recently received clearance from the U.S. Food and Drug Administration to sell FLEX Monoclonal Rabbit Anti-Human Estrogen Receptor ?, Clone EP1 in the United States. The clone has been available in Europe for some time and has enjoyed widespread acceptance. “We […]
SAN JOSE, Calif.- Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its facility in San Jose, Calif. and its Franklin, Mass. site have achieved ISO 13485 certification, an internationally recognized standard of quality management for the design and manufacture of medical devices. The sites in Franklin and San Jose are […]
Nashville, Tenn.– Insight Genetics, which has developed a diagnostic test that can more accurately determine if certain lung cancer patients will respond to targeted therapies, has been selected by the National Cancer Institute (NCI) to participate in the Clinical Assay Development Program (CADP). The CADP is an initiative of NCI’s Division of Cancer Treatment and […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
